Skip to main content

mycophenolate

Generic: MYCOPHENOLATE SODIUM·Brand: MYCOPHENOLATE SODIUM, MYFORTIC

mycophenolate: 3 clinical trials tracked.

mycophenolate evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about mycophenolate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

NCT07412470Registry updated 2026-06-23·Phase 2/Phase 3·SNY
Recruiting

Primary endpoint: Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantation

InterventionalRandomizedopen526 targetStarted 2026-03Completion 2033-0826 sites · Argentina, Australia, Belgium, Chile…Sanofi

A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.

NCT05156710Registry updated 2026-08-21·Phase 2·SNY
Active, not recruiting

Primary endpoint: Cohort A: Treatment failure rate

InterventionalRandomizedopen48 enrolledStarted 2022-06Completion 2026-1027 sites · Canada, France, Germany, Italy…Sanofi

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

NCT04645589Registry updated 2026-06-30
Completed

Primary endpoint: Safety profile of Enteric-coated Mycophenolate Sodium (EC-MPS) on Lupus nephritis patients

Observational69 enrolledStarted 2021-03Completion 2025-086 sites · TaiwanNovartis Pharmaceuticals